title: [Thiotriazoline in the Treatment of Stable Angina Pectoris of II-III Functional Class].
abstract: Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount. Both drugs have demonstrated clinical efficacy equal for all primary and secondary endpoints.
authors.forename: D V
authors.initials: DV
authors.lastname: Kadin
authors.forename: B A
authors.initials: BA
authors.lastname: Chumak
authors.forename: A E
authors.initials: AE
authors.lastname: Filippov
authors.forename: S B
authors.initials: SB
authors.lastname: Shustov
mesh_terms: D000328:Adult; D000368:Aged; D060050:Angina, Stable / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014292:Trimetazidine / Q000008:administration & dosage*; D014665:Vasodilator Agents / Q000008:administration & dosage
chemical_list: D014665:Vasodilator Agents; D014292:Trimetazidine